New promising approach (Phase 2 completed) to delay next-line systemic therapy in mCRPC: MEDCARE trial

[Maxone73]

The MEDCARE trial examined the effectiveness of PDT in delaying the need for NEST (Next-line Systemic Therapy) in patients with oligoprogressive mCRPC. The trial involved 20 patients who received PDT for a total of 38 oligoprogressive lesions. The results showed that PDT resulted in a median NEST-FS of 17 months, meaning that patients were able to delay the start of a new line of systemic treatment for this duration.

Notably, no patients experienced grade ≥3 toxicity from the PDT. This suggests that PDT may be a safe and effective approach for managing oligoprogressive mCRPC, potentially improving patients' quality of life by delaying the need for more aggressive systemic treatment.

prostatewarriors.com/2024/1...